Poster Viewingβ-Trcp-mediated Degradation of FOXN2 Promotes Cell Proliferation and Radioresistance of Lung Cancer Cells

Jun Ma,Y.X. Li,Chao Wan,Jian Huang,You Qin,Bian Wu,Shuangbing Xu,Kunyu Yang,Gang Wu

DOI: https://doi.org/10.1016/j.ijrobp.2017.06.1812

2017-01-01

Abstract:β-Trcp (β-transducin repeat-containing protein), which is substrate-recognition subunit of SCF (SKP1-Cullin1-F-box protein) E3 ligase complexes, plays critical roles in tumorigenesis through ubiquitination and degradation of target proteins. FOX family is a transcription factor involved in organ development and tumorigenesis. Our previous study showed that FOXN2 may be a candidate substrate of β-Trcp. However, it remains largely unknown the radiosensitization effects of FOXN2 and the underlying mechanism in lung cancer cells. Co-immunoprecipitation (Co-Ip) was used to detect the interaction between FOXN2 and β-Trcp1. Ubiquitination assay was used to determine the ubiquitination site of FOXN2 by β-Trcp1. We conducted half-life experiment to determine the degradation rate of FOXN2 and its mutant form (FOXN2-AA) proteins. Using SiRNA technology, we evaluated the effect of FOXN2 on growth and proliferation in lung cancer cells. Colony formation assay and γ-H2AX foci experiment were conducted to assess the radiosensitivity of FOXN2 in lung cancer cells. We demonstrate that FOXN2 interacts with β-Trcp1 and the stability of FOXN2 is negatively controlled by β-Trcp1. Furthermore, FOXN2 is ubiquitinated by β-Trcp1 at the Ser365 and Ser369 site. Moreover, depletion of FOXN2 promotes the proliferation and radioresistance of lung cancer cells. Most importantly, mutant form of FOXN2 (FOXN2-AA) exhibits more potent inhibition ability of cancer cell proliferation and radioresistance. Our results demonstrate that FOXN2 is a new substrate of SCFβ-Trcp and degraded through ubiquitin-proteasome pathway. FOXN2 may act as a tumor suppressor gene in lung cancer cell, which inhibits the cell proliferation and enhances radiosensitivity. Taken together, our findings indicate that the upregulation of FOXN2 may be an underlying therapeutic and radiosensitization target for lung cancer.